Manhal Izzy, Hilary M. DuBrock – 25 April 2022

AASLD created a variety of resources to help hepatologists and liver patients navigate COVID-19.

This is the first AASLD Practice Guidance on the management of malnutrition, frailty, and sarcopenia in patients with cirrhosis

Liver Transplantation (LT) is the treatment of choice for patients with decompensated cirrhosis, acute liver failure, small hepatocellular carcinomas (HCCs), or acute liver failure.

Access to liver transplants (LT) has profoundly altered the management of advanced liver disease.

Hepatocellular Carcinoma (HCC) is now the fifth-most common cancer in the world and the third cause of cancer-related mortality as estimated by the World Health Organization.

This AASLD 2018 Hepatitis B Guidance is intended to complement the AASLD 2016 Practice Guidelines for Treatment of Chronic Hepatitis B1 and update the previous hepatitis B virus (HBV) guidelines from 2009.

Hepatic encephalopathy (HE) is a frequent complication and one of the most debilitating manifestations of liver disease, severely affecting the lives of patients and their caregivers.

Hereditary hemochromatosis (HH) remains the most common, identified, genetic disorder in Caucasians.

Disha Sharma, Gil Ben Yakov, Devika Kapuria, Gracia Viana Rodriguez, Meital Gewirtz, James Haddad, David E. Kleiner, Christopher Koh, Jenna R. E. Bergerson, Alexandra F. Freeman, Theo Heller – 24 April 2022 – Inborn errors of immunity (IEIs) consist of numerous rare, inherited defects of the immune system that affect about 500,000 people in the United States. As advancements in diagnosis through genetic testing and treatment with targeted immunotherapy and bone marrow transplant emerge, increasing numbers of patients survive into adulthood posing fresh clinical challenges.